267 related articles for article (PubMed ID: 27095574)
1. SRC kinase inhibition with saracatinib limits the development of osteolytic bone disease in multiple myeloma.
Heusschen R; Muller J; Binsfeld M; Marty C; Plougonven E; Dubois S; Mahli N; Moermans K; Carmeliet G; Léonard A; Baron F; Beguin Y; Menu E; Cohen-Solal M; Caers J
Oncotarget; 2016 May; 7(21):30712-29. PubMed ID: 27095574
[TBL] [Abstract][Full Text] [Related]
2. Effect of the specific Src family kinase inhibitor saracatinib on osteolytic lesions using the PC-3 bone model.
Yang JC; Bai L; Yap S; Gao AC; Kung HJ; Evans CP
Mol Cancer Ther; 2010 Jun; 9(6):1629-37. PubMed ID: 20484016
[TBL] [Abstract][Full Text] [Related]
3. Effects of Src kinase inhibition by saracatinib (AZD0530) on bone turnover in advanced malignancy in a Phase I study.
Hannon RA; Finkelman RD; Clack G; Iacona RB; Rimmer M; Gossiel F; Baselga J; Eastell R
Bone; 2012 Apr; 50(4):885-92. PubMed ID: 22245630
[TBL] [Abstract][Full Text] [Related]
4. Inhibiting Dickkopf-1 (Dkk1) removes suppression of bone formation and prevents the development of osteolytic bone disease in multiple myeloma.
Heath DJ; Chantry AD; Buckle CH; Coulton L; Shaughnessy JD; Evans HR; Snowden JA; Stover DR; Vanderkerken K; Croucher PI
J Bone Miner Res; 2009 Mar; 24(3):425-36. PubMed ID: 19016584
[TBL] [Abstract][Full Text] [Related]
5. Maternal embryonic leucine zipper kinase inhibitor OTSSP167 has preclinical activity in multiple myeloma bone disease.
Muller J; Bolomsky A; Dubois S; Duray E; Stangelberger K; Plougonven E; Lejeune M; Léonard A; Marty C; Hempel U; Baron F; Beguin Y; Cohen-Solal M; Ludwig H; Heusschen R; Caers J
Haematologica; 2018 Aug; 103(8):1359-1368. PubMed ID: 29748441
[TBL] [Abstract][Full Text] [Related]
6. The Src inhibitor AZD0530 reversibly inhibits the formation and activity of human osteoclasts.
de Vries TJ; Mullender MG; van Duin MA; Semeins CM; James N; Green TP; Everts V; Klein-Nulend J
Mol Cancer Res; 2009 Apr; 7(4):476-88. PubMed ID: 19372577
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of p38alpha mitogen-activated protein kinase prevents the development of osteolytic bone disease, reduces tumor burden, and increases survival in murine models of multiple myeloma.
Vanderkerken K; Medicherla S; Coulton L; De Raeve H; Willems A; Lawson M; Van Camp B; Protter AA; Higgins LS; Menu E; Croucher PI
Cancer Res; 2007 May; 67(10):4572-7. PubMed ID: 17495322
[TBL] [Abstract][Full Text] [Related]
8. Effects of Src-kinase inhibition in cancer-induced bone pain.
De Felice M; Lambert D; Holen I; Escott KJ; Andrew D
Mol Pain; 2016; 12():. PubMed ID: 27094550
[TBL] [Abstract][Full Text] [Related]
9. An osteoprotegerin-like peptidomimetic inhibits osteoclastic bone resorption and osteolytic bone disease in myeloma.
Heath DJ; Vanderkerken K; Cheng X; Gallagher O; Prideaux M; Murali R; Croucher PI
Cancer Res; 2007 Jan; 67(1):202-8. PubMed ID: 17210700
[TBL] [Abstract][Full Text] [Related]
10. The Novel Pan-PIM Kinase Inhibitor, PIM447, Displays Dual Antimyeloma and Bone-Protective Effects, and Potently Synergizes with Current Standards of Care.
Paíno T; Garcia-Gomez A; González-Méndez L; San-Segundo L; Hernández-García S; López-Iglesias AA; Algarín EM; Martín-Sánchez M; Corbacho D; Ortiz-de-Solorzano C; Corchete LA; Gutiérrez NC; Maetos MV; Garayoa M; Ocio EM
Clin Cancer Res; 2017 Jan; 23(1):225-238. PubMed ID: 27440267
[TBL] [Abstract][Full Text] [Related]
11. The effect of the dual PI3K and mTOR inhibitor BEZ235 on tumour growth and osteolytic bone disease in multiple myeloma.
Gan ZY; Fitter S; Vandyke K; To LB; Zannettino AC; Martin SK
Eur J Haematol; 2015 Apr; 94(4):343-54. PubMed ID: 25179233
[TBL] [Abstract][Full Text] [Related]
12. Phase I safety, pharmacokinetics, and inhibition of SRC activity study of saracatinib in patients with solid tumors.
Baselga J; Cervantes A; Martinelli E; Chirivella I; Hoekman K; Hurwitz HI; Jodrell DI; Hamberg P; Casado E; Elvin P; Swaisland A; Iacona R; Tabernero J
Clin Cancer Res; 2010 Oct; 16(19):4876-83. PubMed ID: 20805299
[TBL] [Abstract][Full Text] [Related]
13. The effect of the PI3K inhibitor BKM120 on tumour growth and osteolytic bone disease in multiple myeloma.
Martin SK; Gan ZY; Fitter S; To LB; Zannettino AC
Leuk Res; 2015 Mar; 39(3):380-7. PubMed ID: 25624048
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of saracatinib (AZD0530) in patients with previously treated metastatic colorectal cancer.
Reddy SM; Kopetz S; Morris J; Parikh N; Qiao W; Overman MJ; Fogelman D; Shureiqi I; Jacobs C; Malik Z; Jimenez CA; Wolff RA; Abbruzzese JL; Gallick G; Eng C
Invest New Drugs; 2015 Aug; 33(4):977-84. PubMed ID: 26062928
[TBL] [Abstract][Full Text] [Related]
15. Selective inhibition of Src family kinases by SU6656 increases bone mass by uncoupling bone formation from resorption in mice.
Thouverey C; Ferrari S; Caverzasio J
Bone; 2018 Aug; 113():95-104. PubMed ID: 29751129
[TBL] [Abstract][Full Text] [Related]
16. The proteasome inhibitor, bortezomib suppresses primary myeloma and stimulates bone formation in myelomatous and nonmyelomatous bones in vivo.
Pennisi A; Li X; Ling W; Khan S; Zangari M; Yaccoby S
Am J Hematol; 2009 Jan; 84(1):6-14. PubMed ID: 18980173
[TBL] [Abstract][Full Text] [Related]
17. Erlotinib inhibits osteolytic bone invasion of human non-small-cell lung cancer cell line NCI-H292.
Furugaki K; Moriya Y; Iwai T; Yorozu K; Yanagisawa M; Kondoh K; Fujimoto-Ohuchi K; Mori K
Clin Exp Metastasis; 2011 Oct; 28(7):649-59. PubMed ID: 21688034
[TBL] [Abstract][Full Text] [Related]
18. CCR1 blockade reduces tumor burden and osteolysis in vivo in a mouse model of myeloma bone disease.
Dairaghi DJ; Oyajobi BO; Gupta A; McCluskey B; Miao S; Powers JP; Seitz LC; Wang Y; Zeng Y; Zhang P; Schall TJ; Jaen JC
Blood; 2012 Aug; 120(7):1449-57. PubMed ID: 22618707
[TBL] [Abstract][Full Text] [Related]
19. A phase II trial of the Src kinase inhibitor saracatinib (AZD0530) in patients with metastatic or locally advanced gastric or gastro esophageal junction (GEJ) adenocarcinoma: a trial of the PMH phase II consortium.
Mackay HJ; Au HJ; McWhirter E; Alcindor T; Jarvi A; MacAlpine K; Wang L; Wright JJ; Oza AM
Invest New Drugs; 2012 Jun; 30(3):1158-63. PubMed ID: 21400081
[TBL] [Abstract][Full Text] [Related]
20. Bisphosphonates and osteoprotegerin as inhibitors of myeloma bone disease.
Croucher PI; Shipman CM; Van Camp B; Vanderkerken K
Cancer; 2003 Feb; 97(3 Suppl):818-24. PubMed ID: 12548581
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
